Sensei Biotherapeutics Presents Preclinical Data for

– SNS-101 demonstrated a good pharmacokinetic profile, enhanced anti-tumor results together with anti-PD-1 antibodies and a considerably improved cytokine launch profile as in comparison with a pH-independent VISTA antibody

BOSTON, Sept. 30, 2022 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology firm targeted on the invention and growth of next-generation therapeutics for most cancers, right now introduced further preclinical information on SNS-101, a monoclonal antibody concentrating on the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), on the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The presentation incorporates information from an ongoing collaboration with scientists at Washington University, St. Louis, investigating the mechanism of motion of SNS-101.

“VISTA remains a promising but difficult-to-drug immuno-oncology target due to significant on-target/off-tumor activity. We’re excited to collaborate with Sensei Bio on studies exploring the efficacy and mechanism of action of their conditionally active, pH-dependent VISTA-blocking antibody, SNS-101,” stated Robert D. Schreiber, Ph.D., Andrew M. and Jane M. Bursky Distinguished Professor, Pathology & Immunology on the Washington University School of Medicine in St. Louis and a member of Sensei’s Immuno-Oncology Advisory Board. “In our PD-1-resistant, immunocompetent 1956 tumor model, we observed strong synergistic anti-tumor activity of SNS-101 in combination with PD-1 inhibition, resulting in five out of eight complete responses versus only one out of eight in the PD-1 monotherapy control group.”

“These preclinical data demonstrate that the selectivity of our conditionally active VISTA-blocking antibody has the potential to avoid poor pharmacokinetics from target-mediated drug disposition and lower the risk of cytokine release syndrome, while significantly enhancing the anti-tumor effects of PD-1 blockade selectively within tumors,” stated Edward van der Horst, Ph.D., Senior Vice President, Biologics Discovery & Early Development. “These findings support the scientific rationale for Sensei’s pH-selective approach, which we believe could offer numerous safety and efficacy advantages over pH-independent antibodies targeting VISTA, including the potential to inhibit tumor growth across a range of indications.”

Summary of Key Data:

• SNS-101 potently inhibited the crucial pH-dependent interplay between VISTA and PSGL-1, in addition to interactions with different putative receptors.
• In vitro and in vivo cytokine launch syndrome (CRS) assays show that SNS-101 considerably decreased cytokine induction as in comparison with a pH-independent VISTA antibody, suggesting that SNS-101 has potential to considerably decrease the chance of CRS.
• Pharmacokinetics research show that the pH-sensitive binding of SNS-101 prevented the speedy clearance by target-mediated drug disposition (TMDD) that has been noticed with pH-independent VISTA antibodies.
• SNS-101 demonstrated important enhancement of anti-tumor results together with anti-PD-1 antibodies in a number of syngeneic tumor fashions.

The full poster is offered for viewing on Sensei’s company web site.

About Sensei Biotherapeutics
Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology firm targeted on the invention and growth of subsequent era therapeutics for most cancers. Sensei has designed two distinctive approaches to develop extremely selective therapeutics – its TMAb™ (Tumor Microenvironment Activated biologics) platform, which disables checkpoints and different immunosuppressive indicators within the tumor microenvironment to unleash current T cells towards tumors, and the ImmunoPhage™ platform, which trains new T cells to acknowledge and kill malignant cells. Using its TMAb platform, the corporate is growing SNS-101, a completely human antibody designed to dam the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively solely inside the low pH tumor microenvironment, the place VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The firm can be utilizing its platforms to develop different preclinical applications concentrating on a number of stable tumor indications. For extra info, please go to www.senseibio.com, and comply with the corporate on Twitter @SenseiBio and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
Any statements contained on this press launch that don’t describe historic details might represent forward-looking statements as that time period is outlined within the Private Securities Litigation Reform Act of 1995. These statements could also be recognized by phrases and phrases comparable to “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and comparable expressions, and are primarily based on Sensei’s present beliefs and expectations. These forward-looking statements embrace expectations concerning the event of Sensei’s product candidates and platforms, together with SNS-101; the potential security profile of Sensei’s product candidates, together with SNS-101; and the potential advantages of SNS-101, together with the potential to beat pharmacokinetic and issues of safety related to concentrating on the VISTA immune checkpoint, together with target-mediated drug disposition and cytokine launch syndrome, in addition to the potential to reinforce anti-tumor results together with anti-PD-1 antibodies and inhibit tumor progress throughout a spread of indications. These statements contain dangers and uncertainties that might trigger precise outcomes to vary materially from these mirrored in such statements. Risks and uncertainties that will trigger precise outcomes to vary materially embrace uncertainties inherent within the growth of therapeutic product candidates, comparable to the chance that anyone or extra of Sensei’s product candidates is not going to be efficiently developed or commercialized; the chance of delay or cessation of any deliberate scientific trials of Sensei’s product candidates; the chance that prior outcomes, comparable to indicators of security, exercise or sturdiness of impact, noticed from preclinical research, together with the preclinical research described on this press launch, is not going to be replicated or is not going to proceed in ongoing or future research or scientific trials involving Sensei’s product candidates; the chance that Sensei’s product candidates or procedures in reference to the administration thereof is not going to have the security or efficacy profile that we anticipate; dangers related to Sensei’s dependence on third-party suppliers and producers, together with sole supply suppliers, over which we might not all the time have full management; dangers concerning the accuracy of our estimates of bills, capital necessities and wishes for further financing; and different dangers and uncertainties which might be described in Sensei’s Annual Report on Form 10-Okay filed with the U.S. Securities and Exchange Commission (SEC) on March 15, 2022 and Sensei’s different Periodic Reports filed with the SEC. Any forward-looking statements converse solely as of the date of this press launch and are primarily based on info obtainable to Sensei as of the date of this launch, and Sensei assumes no obligation to, and doesn’t intend to, replace any forward-looking statements, whether or not because of new info, future occasions or in any other case.

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
[email protected]

Media Contact:
Chris Railey
Ten Bridge Communications
[email protected]